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Mantle cell lymphoma is an aggressive tumor for which new drugs targeting underlying molecular mecha-
nisms are opening promising avenues. A recent study has elucidated the basis for targeting B cell receptor
signaling in these lymphomas and identified somatic mutations in NF-kB regulatory genes that confer
resistance to this therapy.Mantle cell lymphoma (MCL) is an aggres-
sive lymphoid neoplasia derived from
mature B cells and is considered incur-
able with current therapies. The primary
oncogenic driver is the t(11;14)(q13;q32)
translocation, which causes cyclin D1
overexpression. This event is usually
followed by additional chromosomal
alterations that target genes regulating
DNA damage response, cell cycle, and
cell survival pathways (Jares et al.,
2012). The clinical and biological features
of MCL now seem more heterogeneous
than initially recognized. Recent studies
have identified a subset of tumors with
an indolent behavior that tends to pre-
sent with leukemic instead of extensive
nodal disease. The tumor cells have sim-
ple karyotypes, frequent hypermutated
IGHV, and a gene expression signature
that does not include SOX11, a transcrip-
tion factor that promotes oncogenic
growth of conventional MCL (Jares et al.,
2012; Vegliante et al., 2013). These
indolent tumors may acquire additional
oncogenic alterations and eventually
progress to a more aggressive form.
Although the outcome for MCL patients
has improved globally in past years
through the use of new combined
immunochemotherapy and intensive
regimens such as stem cell transplan-
tation, many patients will relapse and
eventually die of the disease.
Increased understanding of the mole-
cular mechanisms driving MCL has
facilitated the development of new
therapies that offer promising avenues
(Pe´rez-Gala´n et al., 2011). The relevance
of B cell receptor (BCR) signaling to the
pathogenesis of several lymphomas
has propelled investigation of a series of
drugs that interfere with these pathways(Young and Staudt, 2013). Initial clinical
studies with some of these agents, partic-
ularly ibrutinib, a covalent inhibitor of
the Bruton tyrosine kinase (BTK), have
yielded substantial responses in different
lymphoid neoplasms, including diffuse
large B cell lymphoma (DLBCL), chronic
lymphocytic leukemia (CLL), and MCL
(Young and Staudt 2013; Wang et al.,
2013). However, the encouraging results
obtained for MCL were somewhat sur-
prising, because, contrary to DLBCL or
CLL, evidence supporting a pathogenic
role for BCR stimulation in MCL were
limited. Suggestive findings from recent
studies in MCL have identified a restricted
immunoglobulin gene repertoire and often
stereotyped configurations of the BCR,
supporting the role of antigen selection
in a subset of these tumors. In addition,
different kinases in BCR signaling,
including SYK, LYN, and BTK, may be
amplified or phosphorylated in primary
MCL, supporting the activation of this
pathway in certain tumors (reviewed in
Pe´rez-Gala´n et al., 2011 and Jares et al.,
2012). A recent study by Wang et al.
(2013) showed complete or partial re-
sponses to ibrutinib in up to 68% of
patients who had failed to respond
to other therapies. This response was
higher than expected based on known
BCR alterations in MCL. Beyond the
positive clinical impact, this study high-
lighted our limited understanding of
the molecular bases for both the high
response rate and the resistance to
BTK inhibition in these tumors.
In a recent study in Nature Medicine,
Rahal et al. (2013) found answers to
some of the open questions surrounding
clinical experience with ibrutinib in MCL.
Using a large-scale pharmacologicalCancer Cellprofiling strategy across more than 100
hematological cell line models, the au-
thors identified 4 MCL lines that were
highly sensitive to the BCR signaling
inhibitors ibrutinib and sotrastaurin
and 6 lines that were resistant to the
treatments. Intriguingly, both subsets
of sensitive and resistant cell lines were
dependent on IKKb-NF-kB signaling,
confirming previously reported constitu-
tive NF-kB activation in MCL (Pham
et al., 2003). However, the sensitive, but
not the resistant, cells were addicted to
signaling through the CARD11-BCL10-
MALT1 (CBM) complex downstream of
BTK and PKC, which sustained activation
of the classical NF-kB pathway (Figure 1).
To understand the possible mechanisms
underlying NF-kB activation in resistant
cells, the authors performed RNA se-
quencing and found inactivating muta-
tions of TRAF2 and TRAF3 in two of the
resistant cell lines. TRAF2 and TRAF3
are negative regulators of the alternative
NF-kB signaling pathway interacting
with cIAP1 and cIAP2 (gene products
of BIRC2 and BIRC3, respectively)
to downregulate NIK (encoded by
MAP3K14), a central kinase in this
pathway that promotes processing of
the NF-kB precursor p100 into the active
p52 isoform (Figure 1). Loss of TRAF2
and TRAF3 were essential for survival of
the cells suggesting that NIK could be a
new target in MCL that specifically bear
these genetic alterations. Interestingly,
three of the other resistant MCL lines
in which the authors did not find similar
mutations are known to be infected
by Epstein-Barr virus (EBV), an activator
of the alternative NF-kB pathway. Intrigu-
ingly, there was one resistant cell line
without clear evidence of alternative25, January 13, 2014 ª2014 Elsevier Inc. 7
Figure 1. Somatic Mutation and Activation of the NF-kB Pathway in MCL
Activation of the classical and alternative NF-kB pathway in MCL may occur by chronic active BCR signaling and other mechanisms. Genomic sequencing
studies have identified mutations in several elements of this regulatory pathway (denoted by red asterisks). Chronic active BCR (A) or Toll-like receptor (TLR)
(B) signaling activate classical NF-kB pathway. MCL that is dependent on BCR activation (A) may be blocked by BCR signaling inhibitors. Somatic mutations
in the inhibitors of the alternative pathways (C) cIAP1 and cIAP2 (gene products of BIRC2 and BIRC3, respectively) and TRAF2/3 activate the alternative
NF-kB pathway and confer resistance to inhibitors of the BCR signaling pathway. Somatic mutations in other elements of these pathways (CARD11, IKKb,
encoded by IKBKB, TLR2, and NIK, encoded by MAP3K14) have been also found in MCL by whole exome or genome sequencing .
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negative for EBV and TRAF2/3mutations,
suggesting that other mechanisms
may create resistance to BCR inhibitors
in MCL.
Rahal et al. (2013) analyzed the pres-
ence of mutations in genes encoding
members of the alternative NF-kB path-
ways TRAF2, TRAF3, BIRC2, BIRC3,
and MAP3K14 across 165 primary MCLs
and found TRAF2 and BIRC3 mutations
in 6% and 10% of the cases, respectively.
These observations are concordant with
the findings in our recent whole genome
and exome sequencing study of MCL
in which we found BIRC3 mutations in
6% of cases (Bea` et al., 2013). BIRC3 is
located at 11q22.2, a region frequently
deleted in MCL. In our study, virtually all
BIRC3 mutations were associated with
11q deletions, including a case without8 Cancer Cell 25, January 13, 2014 ª2014 ElATM mutations, suggesting that, in addi-
tion to the dominant negative effect of
these mutations suggested by Rahal
et al. (2013), the deletion of the normal
BIRC3 allele may confer an additional
advantage to the cells. Although we did
not observed TRAF2/3 mutations, we
found mutations in other genes of the
classical and alternative NF-kB pathway,
including recurrent activating mutations
in TLR2 as well as mutations in CARD11,
MAP3K14 (NIK), and IKBKB (IKKb)
(Figure 1). Although the functional impli-
cations of some of these mutations need
to be confirmed, together, the studies
suggest that genetic alterations in the
NF-kB pathway in MCL may be more
common than initially thought.
The observations of Rahal et al. (2013),
if confirmed in primary tumor cells, may
have important clinical implications. Thesevier Inc.detection of RelB cleavage, as a down-
stream effect of PKC-CBM activity, and
low levels of p52 identified cells sensitive
to BCR inhibitors. In contrast, tumors
with high p52 levels and genetic lesions
in the alternative NFkB pathway predicted
resistance to these agents. Therefore,
these alterations may be useful bio-
markers for selecting targeted therapies
in MCL. The involvement of the alternative
NF-kB pathway in resistance to BCR
inhibitors may also be of interest for
other lymphoid neoplasms. Mutations in
genes of the alternative (BIRC3, TRAF3,
and MAP3K14) and classical (TNFAIP3
and IKBKB) NF-kB pathways have been
described in 36% of splenic marginal
zone lymphomas (Rossi et al., 2011) and
24% of advanced or chemoresistant
CLL (Rossi et al., 2012). The functional
relationship between these mutations
Cancer Cell
Previewsand the response to new therapies in lym-
phomas deserves further exploration.
Additional mechanisms, such as muta-
tions in BTK or in other targets of the
new drugs, may also emerge and confer
resistance in MCL. The preclinical results
presented by Rahal et al. (2013) provide
critical insights into understanding the
mechanisms of response to new drugs
and suggest innovative therapeutic
strategies for tumors refractory to BCR
signaling inhibitors. The study also high-
lights the increasing clinical interest of
sequencing tumors to guide the selection
of new therapies in lymphoid neoplasms.
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Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents
bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce
the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for
MM growth.The story of the use of thalidomide and
related compounds in the treatment of
multiple myeloma (MM) represents a
remarkable case of bedside to bench
research. Thalidomide may have first
been discovered during World War II as
a potential antidote to nerve gas and
was developed as a sedative used for
morning sickness in the 1950s. This
culminated in a great medical tragedy
because of the extraordinary teratogenic
effects on limb development. The drug
was abandoned but was later explored
for the treatment of leprosy ulcers, HIV/
AIDS, and autoimmune diseases. Theseanti-inflammatory effects were linked to
inhibition of tumor necrosis factor secre-
tion, providing an early indication that
thalidomide functioned as an immune
modulatory drug (IMiD). Dr. Judah Folk-
man and colleagues subsequently found
that thalidomide inhibited tumor associ-
ated angiogenesis. Folkman’s advice
to a patient to try thalidomide in MM
(http://www.nytimes.com/1999/11/18/us/
thalidomide-found-to-slow-a-bone-cancer.
html) led to a seminal study showing
a 32% response rate of MM patients to
a single agent thalidomide treatment,
including complete responses in severalpatients refractory to all prior therapies
(Singhal et al., 1999). Thalidomide in
combination with dexamethasone as an
initial therapy yields response rates of
>60%, while lenalidomide, a chemically
similar IMiD with fewer constitutional
side effects, plus dexamethasone yields
responses in 80% of patients. The use
of these IMiDs along with the protea-
some inhibitor bortezomib has extended
the median survival of MM patients to
greater than 7 years. This remarkable
progress occurred in the absence of
clear molecular and biological mecha-
nisms of action of thalidomide,25, January 13, 2014 ª2014 Elsevier Inc. 9
